Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Translational and Clinical Pharmacology Pub Date : 2023-09-01 Epub Date: 2023-08-23 DOI:10.12793/tcp.2023.31.e12
Yeonseo Jang, Jihyun Kang, Sejung Hwang, Jae-Yong Chung, Joo-Youn Cho
{"title":"Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine.","authors":"Yeonseo Jang,&nbsp;Jihyun Kang,&nbsp;Sejung Hwang,&nbsp;Jae-Yong Chung,&nbsp;Joo-Youn Cho","doi":"10.12793/tcp.2023.31.e12","DOIUrl":null,"url":null,"abstract":"<p><p>Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides' (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis. Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of scientists and researchers in recent years. Previous studies have also observed CP-I and CP-III levels as clinical biomarkers for predicting OATP1B inhibition in drug-drug interaction studies. To establish an accurate ultra-high performance liquid chromatography-mass spectrometry method for the quantitation of CP-I and CP-III, we reviewed previous methodological publications and applied them to a clinical pharmacology study using a human urine matrix. We used 13.25 M formic acid as a working solution for internal standards (CP-I <sup>15</sup>N<sub>4</sub> and CP-III d<sub>8</sub>) to avoid isobaric interference. The calibration curve showed good linearity in the range of 1-100 ng/mL, with a correlation coefficient (<i>R<sup>2</sup></i>) higher than 0.996 in each validation batch. Both the between-run and within-run assays achieved good precision and accuracy, and we found that both CP-I and CP-III were stable in the pre-study validation. The method exhibited suitable dilution integrity, allowing for the re-analysis of samples with concentrations exceeding the upper limit of quantification through dilution. Overall, the application of the described method in a clinical study revealed that it can be utilized effectively to monitor drug-drug interactions mediated by OATP1B.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":"31 3","pages":"139-147"},"PeriodicalIF":1.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/46/tcp-31-139.PMC10551744.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational and Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12793/tcp.2023.31.e12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides' (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis. Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of scientists and researchers in recent years. Previous studies have also observed CP-I and CP-III levels as clinical biomarkers for predicting OATP1B inhibition in drug-drug interaction studies. To establish an accurate ultra-high performance liquid chromatography-mass spectrometry method for the quantitation of CP-I and CP-III, we reviewed previous methodological publications and applied them to a clinical pharmacology study using a human urine matrix. We used 13.25 M formic acid as a working solution for internal standards (CP-I 15N4 and CP-III d8) to avoid isobaric interference. The calibration curve showed good linearity in the range of 1-100 ng/mL, with a correlation coefficient (R2) higher than 0.996 in each validation batch. Both the between-run and within-run assays achieved good precision and accuracy, and we found that both CP-I and CP-III were stable in the pre-study validation. The method exhibited suitable dilution integrity, allowing for the re-analysis of samples with concentrations exceeding the upper limit of quantification through dilution. Overall, the application of the described method in a clinical study revealed that it can be utilized effectively to monitor drug-drug interactions mediated by OATP1B.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人类尿液中OATP1B1内源性代谢物粪卟啉I和III的定量。
共卟啉(CP)-I和CP-III是有机阴离子转运多肽(OATP)活性的标志物,它们是源自血红素合成的卟啉代谢产物。此外,作为OATP1B内源性代谢产物的CP-I和CP-III近年来逐渐引起了科学家和研究人员的注意。先前的研究也观察到CP-I和CP-III水平作为预测药物相互作用研究中OATP1B抑制的临床生物标志物。为了建立一种准确的超高效液相色谱-质谱法来定量CP-I和CP-III,我们回顾了以前的方法学出版物,并将其应用于使用人类尿液基质的临床药理学研究。我们使用13.25M甲酸作为内标物(CP-I 15N4和CP-III d8)的工作溶液,以避免等压干扰。校准曲线在1-100 ng/mL范围内显示出良好的线性,每个验证批次的相关系数(R2)均高于0.996。批间和批内分析都获得了良好的精度和准确性,我们发现CP-I和CP-III在研究前验证中都是稳定的。该方法表现出适当的稀释完整性,允许通过稀释对浓度超过定量上限的样品进行重新分析。总之,所述方法在临床研究中的应用表明,它可以有效地用于监测OATP1B介导的药物-药物相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Translational and Clinical Pharmacology
Translational and Clinical Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.60
自引率
11.10%
发文量
17
期刊介绍: Translational and Clinical Pharmacology (Transl Clin Pharmacol, TCP) is the official journal of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT). TCP is an interdisciplinary journal devoted to the dissemination of knowledge relating to all aspects of translational and clinical pharmacology. The categories for publication include pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics, pharmacoepidemiology, pharmacovigilence, and human pharmacology. Studies involving animal models, pharmacological characterization, and clinical trials are appropriate for consideration.
期刊最新文献
Analyzing collaborations in clinical trials in Korea using association rule mining. Cardiotoxicity evaluation of two-drug fixed-dose combination therapy under CiPA: a computational study. Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic. PMDA initiatives to enhance drug development via multi-regional clinical trials. Research on unintroduced new drugs in South Korea from 2011 to 2020: approaches to prioritization and strategy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1